Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...

Regeneron Pharmaceuticals (NASDAQ:REGN) on Friday topped Street forecasts with its Q2 financials, thanks mainly to U.S. sales ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

Regeneron reported quarterly revenue contraction of 4% year on year, which was largely driven by declines in its Eylea franchise. Original dose Eylea declined 39% year on year and 38% sequentially ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

The FDA will likely announce whether it has decided to approve Regeneron's (REGN) Elyea today, as today is the drug's PDUFA date. Eylea is a treatment for neovascular age-related macular ...

FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020.